Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-day versus 5-day CLAG before allo-HSCT in children with refractory, relapsed, or high-risk acute leukemia
ChiCTR2200065829Phase 3Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Nov 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cladribine, cytarabine and granulocyte colony-stimulating factor in Acute Leukaemia (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: 2-year disease-free survival and Relapse rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
cladribinecytarabinegranulocyte colony-stimulating factor
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on ChiCTR2200065829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065829.